The FDA feedback provides a clearer regulatory path for fasedienol, but the company still needs to design, conduct, and fund a Phase 3 study. Watch for the submission of a revised protocol and any financing announcements to support the trial, given the $7M market cap and no disclosed cash position.
Drug in focus
VTGN drug pipeline →fasedienol
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 3 (completed — two of three Phase 3 trials failed)
- Time to market
- Unknown — at least 3-5+ years if a new Phase 3 trial is required, with no guarantee of FDA acceptance of the proposed path
- Next catalyst
- None dated
What to watchFasedienol has now failed two consecutive Phase 3 trials (PALISADE-3 Dec 2025, PALISADE-4 June 2026). The stock traded at ~$2.04 before the PALISADE-4 miss and collapsed to ~$0.25, a ~$10M market cap. The company plans an FDA meeting for a potential new trial path, but the path to approval looks extremely long and uncertain. Watch for dilution risk as the company may need financing to fund any future trial.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $0.1844entry
- T+1 · 7d ago −0.70%α −0.34% · $0.1831
- T+5 · 21h ago −0.05%α +1.64% · $0.1843
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vistagen announced FDA feedback from a Type C meeting for its lead candidate fasedienol in social anxiety disorder. The FDA provided constructive guidance on using the LSAS as a primary endpoint in a future Phase 3 study and recognized fasedienol's safety profile. The company plans to submit a revised protocol and pursue development for the overall treatment of SAD, but no financial data, trial results, or approval timeline were disclosed.
Key Facts
- Vistagen held a Type C meeting with the FDA regarding fasedienol for social anxiety disorder (SAD).
- FDA provided constructive feedback on using the Liebowitz Social Anxiety Scale (LSAS) as the primary endpoint in a future Phase 3 study.
- FDA recommended interim assessments using eDiaries and qualitative patient surveys to evaluate acute and longer-term effects.
- FDA recognized fasedienol's reported safety profile and potential to benefit a broad SAD population.
- Vistagen plans to focus on the general SAD population and pursue overall (not just acute) treatment of SAD.
- The company will submit a revised Phase 3 protocol to the FDA.
- No financial figures, trial results, or specific approval timelines were provided.
Financial Impact
No financial impact disclosed; the filing is a regulatory update with no stated costs, revenues, or funding commitments.
Risk Factors
- No assurance that FDA feedback will result in a successful registrational pathway.
- Future Phase 3 trials may fail to demonstrate safety and efficacy for overall SAD treatment.
- Existing clinical data and future study outcomes may be insufficient to support regulatory approval.
- The company may not secure sufficient financing to advance its development plans.
- FDA may require additional studies or information beyond current plans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-071910 |
| Document: vtgnex99111092026.htm | 0001628280-26-071910 |
| Document: 0001628280-26-071910-index-headers.html | 0001628280-26-071910 |
| Document: 0001628280-26-071910-index.html | 0001628280-26-071910 |
| Document: 0001628280-26-071910.txt | 0001628280-26-071910 |
Track record
21 reports on VTGN
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
- Nov 9, 20267d ago 8-K Neutral 4/10 Viewing Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
- Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers